Tag: pharmaceuticals

  • FDA Approves Depression Drug for Musculoskeletal Pain

    Pharmaceutical manufacturer Eli Lilly and Company in Indianapolis, Indiana said that the U.S. Food and Drug Administration (FDA) has approved its drug Cymbalta (duloxetine HCl) for the management of chronic musculoskeletal pain.  FDA already approved Cymbalta to treat major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia. The…

  • Research Institutes Collaborate on Cancer Nanomedicine

    Five research institutions have formed the Texas Center for Cancer Nanomedicine (TCCN) in Houston to develop nanotechnologies to improve outcomes for patients with ovarian or pancreatic cancers. TCCN is funded by a five-year, $16 million grant from National Cancer Institute. The five institutions taking part in TCCN include University of Texas MD Anderson Cancer Center,…

  • FDA Designates Anthrax Treatment Candidate as Orphan Drug

    Emergent BioSolutions Inc., a biotechnology company in Rockville, Maryland, says the U.S. Food and Drug Administration (FDA) has designated as an orphan drug its human anthrax monoclonal antibody AVP-21D9, in development for the treatment of inhalation anthrax. FDA grants orphan status to drugs and biologics being developed to treat rare conditions, specifically those affecting fewer…

  • Four Biotechs Land Affordable Care Act Grants

    Four biotechnology companies reported the awarding of grants under a provision in the Patient Protection and Affordable Care Act of 2010, known popularly as the Affordable Care Act. The Act adds to Section 48D of the Internal Revenue Code a provision called the Qualifying Therapeutic Discovery Project Credit. This credit funds projects that show potential…

  • New Initiative to Speed Pain Treatments

    The U.S. Food and Drug Administration (FDA) selected University of Rochester Medical Center in Rochester, New York to lead a new initiative — Analgesic Clinical Trial Innovations, Opportunities, and Networks (ACTION) — to identify better pain treatments more quickly. FDA awarded Rochester a $1 million contract to launch the program that brings together professional societies,…

  • FDA Approves Schizophrenia Drug

    Sunovion Pharmaceuticals Inc. in Marlborough, Massachusetts says that the U.S. Food and Drug Administration (FDA) approved its drug Latuda (lurasidone HCl) for the treatment of schizophrenia. Latuda is an oral, once-daily antipsychotic in tablet form, offering a treatment for patients with schizophrenia. It is expected to be available in the U.S. during the first quarter…

  • Start Up Licenses Nuclear Imaging Drug Compounds

    Clarity Pharmaceuticals Pty Ltd, a new company in Australia, has licensed technology developed by the University of Melbourne and the Australian Nuclear Science and Technology Organisation (ANSTO). The technology involves compounds developed by scientists from ANSTO and the University of Melbourne for use in positron emission tomography. Positron emission tomography (PET) is a test that…

  • Drug-Related Hospitalizations Double for Age 45+

    The number of hospital admissions for Americans age 45 and older from medication and drug-related conditions doubled between 1997 and 2008, according to a report released today by the Agency for Healthcare Research and Quality (AHRQ), in the U.S. Department of Health and Human Services. AHRQ defines medication and drug-related conditions to include effects of…

  • Magnets Improve Understanding of Influenza Drugs

    Using powerful magnets [sponsored link] to scan proteins’ atomic structures, scientists at Florida State University (FSU) in Tallahassee and Brigham Young University in Provo, Utah are close to understanding why some drugs to treat the influenza A virus have become less effective, and how new drugs can replace them. FSU has patented this magnet-screening process…

  • DoD Awards Contract for Bioweapon Therapies

    Morphotek Inc., a developer of protein and antibody products in Exton, Pennsylvania, said it received a $2.5 million contract from the U.S. Department of Defense (DoD) to fund further development of the company’s monoclonal antibody therapies against disease-causing staphylococcal strains and toxins. In February 2008, Morphotek received funding to support initial development of these therapies.…